Companies › Immutep S.A.S.
1 active drug program in 3 registered trials: 1 Phase 3, 1 Phase 2, 1 Phase 1; Oncology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| eftilagimod alfa Lymphocyte activation gene 3 protein vaccine antigen | LAG3 | Phase 3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC); Neoadjuvant; Solid Tumors | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03252938 | eftilagimod alfa | Phase 1 | Solid Tumors | Oncology | Sep 2026 |
| NCT06128863 | eftilagimod alfa | Phase 2 | Neoadjuvant | Oncology | Apr 2027 |
| NCT06726265 | eftilagimod alfa | Phase 3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | Oncology | Jun 2027 |
Cash and short-term investments of 130m AUD on 2025-06-30; operating cash outflow about 62m AUD a year; runway about 25 months at that burn, to Jul 2027; 2 of 2 coming phase 2-3 readouts fall inside that runway
Regeneron Pharmaceuticals Merck & Co. (MSD) Bristol-Myers Squibb Roche Akeso Shenyang Sunshine Pharmaceutical Shanghai Henlius Biotech
ADC Therapeutics Candel Therapeutics Actinium Pharmaceuticals Maia Biotechnology K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.